{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Recurrent+Malignant&page=2",
    "query": {
      "condition": "Glioma, Recurrent Malignant",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma%2C+Recurrent+Malignant&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:33:39.633Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00734864",
      "title": "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Gliosarcoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "enzyme-inducing anti-epileptic drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-06",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734864"
    },
    {
      "nct_id": "NCT05406700",
      "title": "Niraparib In Recurrent IDH 1/2 Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Low-grade Glioma",
        "IDH2 Gene Mutation",
        "Recurrent Glioma",
        "IDH1 Mutation",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Resection/Treatment with Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-05-18",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05406700"
    },
    {
      "nct_id": "NCT00694330",
      "title": "Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "GM-K562 Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2008-06",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694330"
    },
    {
      "nct_id": "NCT00025675",
      "title": "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 105,
      "start_date": "2001-10-09",
      "completion_date": "2010-01-02",
      "has_results": false,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025675"
    },
    {
      "nct_id": "NCT00002971",
      "title": "O(6)-Benzylguanine in Treating Patients With Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1997-06-19",
      "completion_date": "2009-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-06-27",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002971"
    },
    {
      "nct_id": "NCT00045721",
      "title": "Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "polifeprosan 20 with carmustine implant",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 3,
      "start_date": "2003-03",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2009-10-16",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045721"
    },
    {
      "nct_id": "NCT00005811",
      "title": "Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AIDS-related Diffuse Large Cell Lymphoma",
        "AIDS-related Diffuse Mixed Cell Lymphoma",
        "AIDS-related Diffuse Small Cleaved Cell Lymphoma",
        "AIDS-related Immunoblastic Large Cell Lymphoma",
        "AIDS-related Lymphoblastic Lymphoma",
        "AIDS-related Peripheral/Systemic Lymphoma",
        "AIDS-related Primary CNS Lymphoma",
        "AIDS-related Small Noncleaved Cell Lymphoma",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "HIV-associated Hodgkin Lymphoma",
        "Leptomeningeal Metastases",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 77,
      "start_date": "2000-04",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-02-21",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005811"
    },
    {
      "nct_id": "NCT04222309",
      "title": "Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma",
        "Glioma, Malignant",
        "Glioblastoma",
        "Glioblastoma Multiforme",
        "Glioblastoma Multiforme of Brain",
        "GBM",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Laparoscopically harvested omental free flap",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-06",
      "completion_date": "2026-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04222309"
    },
    {
      "nct_id": "NCT04870944",
      "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Midline Glioma, H3 K27-Altered",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Diffuse Midline Glioma, H3 K27-Altered",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspirate",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "FACT Complex-targeting Curaxin CBL0137",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 63,
      "start_date": "2022-01-28",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04870944"
    },
    {
      "nct_id": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Solid Tumor",
        "CRAF Gene Amplification",
        "RAF1 Gene Amplification",
        "BRAF Gene Fusion",
        "BRAF Fusion",
        "CRAF Gene Fusion",
        "CRAF Fusion",
        "RAF1 Gene Fusion",
        "RAF1 Fusion",
        "Thyroid Cancer, Papillary",
        "Spitzoid Melanoma",
        "Pilocytic Astrocytoma",
        "Pilocytic Astrocytoma, Adult",
        "Non Small Cell Lung Cancer",
        "Non-Small Cell Adenocarcinoma",
        "Colorectal Cancer",
        "Pancreatic Acinar Carcinoma",
        "Spitzoid Malignant Melanoma",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma",
        "MAP Kinase Family Gene Mutation",
        "RAF Mutation"
      ],
      "interventions": [
        {
          "name": "Tovorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-07-15",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-05-21T22:33:39.633Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04985604"
    }
  ]
}